Research ArticleCancer

An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors

See allHide authors and affiliations

Science Translational Medicine  04 Oct 2017:
Vol. 9, Issue 410, eaal4291
DOI: 10.1126/scitranslmed.aal4291

Double trouble for solid tumors

Because the endogenous immune response is not enough to clear a patient’s cancer, therapies are being designed to redirect T cells to tumor cells. This can be done by engineering the cells ex vivo, such as in CAR T cell therapy, or in vivo, such as with bispecific antibodies. Ishiguro et al. describe the development and preclinical testing of a bispecific antibody recognizing CD3 and glypican 3, a common antigen on solid tumors. This bispecific antibody was effective in a variety of mouse cancer models, even when treatment was initiated after the tumor was quite large. Treatment also appeared to be safe when administered to monkeys. These results suggest further development of this antibody for therapeutic use in multiple cancer types.